Zhengye Biotechnology Holding Ltd
corporate_fare Company Profile
Zhengye Biotechnology Holding Ltd (NASDAQ:ZYBT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 7 items for ZYBT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-06, rated 7/10. Across its 7 most recent items scored 7 or higher, the top rating is 9/10, with 6 rated 8 or above. Recent SEC coverage for ZYBT spans 6-K, 20-F.
Recent high-impact activity:
- Zhengye Biotechnology Regains Nasdaq Compliance, Removing Delisting Risk
- Zhengye Biotechnology Receives Nasdaq Delisting Warning for Sub-$1.00 Stock Price
- Zhengye Biotechnology Reports 21-Cent Loss Per Share for 2025
- Zhengye Biotechnology Reports Substantial FY2025 Net Loss, Revenue Decline, and Material Weakness in Internal Controls; Adopts Dual-Class Share Structure
- Shareholders Approve Reverse Stock Split and Reclassification
Financial Snapshot
Short Interest & Short Volume
3.63 days to coverFINRA reported short interest of 137,172 shares in ZYBT as of the September 15, 2026 settlement, a 21.1% decrease from the prior period — about 3.6 days to cover at its recent average daily volume. On October 2, 2026, 5.8% of ZYBT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
ZYBT files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.